预约演示
更新于：2025-11-01
Albiglutide
阿必鲁肽
更新于：2025-11-01
概要
基本信息
原研机构 |
在研机构- |
权益机构- |
最高研发阶段撤市 |
首次获批日期 欧盟 (2014-03-20), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
Sequence Code 39861
来源: *****
关联
43
项与 阿必鲁肽 相关的临床试验NCT05220917
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
NCT03015519
A Randomized, Double-blind, Placebo Controlled, Multi-center Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Albiglutide for the Treatment of Type 2 Diabetes Mellitus in Pediatric Patients
NCT02750930
An Open-label Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Subjects With Type 2 Diabetes Mellitus
100 项与 阿必鲁肽 相关的临床结果
登录后查看更多信息
100 项与 阿必鲁肽 相关的转化医学
登录后查看更多信息
100 项与 阿必鲁肽 相关的专利（医药）
登录后查看更多信息
221
项与 阿必鲁肽 相关的文献（医药）2025-08-11CURRENT PHARMACEUTICAL DESIGN
An Insight into Pharmaceutical Design and Pharmacokinetic Characteristics of GLP-1 RAs
Article
作者: Khyat, Nada O. ; Alsubahi, Ramzyah A. ; Alamoudi, Mariam K. ; Alsibyani, Rawan W. ; Zayed, Mohamed F. ; Alshami, Rahaf Z.
Introdcution::
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are among the most effective
treatments for type 2 diabetes mellitus (T2DM). GLP-1 RAs stimulate pancreatic receptors, improving
glycemia by boosting insulin secretion while decreasing glucagon secretion. GLP-1 receptors are present in
pancreatic tissue. They are also found in extra-pancreatic tissue and have been shown to reduce body weight
while also protecting the heart and endothelial cells. The most prevalent types of GLP-1 RAs can be injected
twice daily (exenatide), once daily (lixisenatide and liraglutide), or once weekly (albiglutide, dulaglutide, exenatide
once, semaglutide, tirzepatide). GLP-1 receptor agonists also reduce gastric emptying, preventing substantial
post-meal glycaemic increases. Many publications have been written regarding GLP-1 RAs, covering
various features of this family. However, the purpose of this study is to investigate the pharmacological design
models and pharmacokinetic characteristics of the most regularly used members of this class, as well as
to highlight contemporary developments in GLP-1 RAs. It also describes the physicochemical features, techniques
of manufacture, the effects of molecular structure, and structural modifications on pharmacological activity.
Methods::
The literature review was completed using a structured approach to identify and integrate relevant
literature. It involved a broad search of reputable medical databases using inclusion and exclusion criteria.
Result::
They are classified as short-acting or long-acting based on the length of their action. Short-acting
GLP-1 RAs and long-acting GLP-1 RAs have differing efficacy profiles. Furthermore, the methods of administration,
mode of action, and side effects of these medications are relevant to their pharmacological design
and pharmacokinetic properties.
Discussion::
The treatment of type 2 diabetes and obesity has evolved with the advent of GLP-1 RAs. These
drugs have a multifaceted approach, emphasizing glycemic regulation, weight loss, and reduction of cardiovascular
risk. Their unique mode of action, strong safety profile, and ability to be individualized according to
each patient's needs make them a valuable therapeutic option in the management of metabolic disorders. Their
pharmacological activities are also influenced by their different structural and pharmacokinetic properties.
Conclusion::
GLP-1 RAs have a complex strategy due to their pharmacological nature. The variations in their
design have led to various members with varying pharmacodynamic and pharmacokinetic features.
2025-08-01JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists
Article
作者: Federici, Massimo ; Angiolillo, Dominick J ; Bernardi, Marco ; Sciarretta, Sebastiano ; Simeone, Beatrice ; Benenati, Stefano ; Ortega-Paz, Luis ; Rocco, Erica ; Greco, Ernesto ; Spadafora, Luigi ; Mehran, Roxana ; Crea, Filippo ; Laudani, Claudio ; Sarto, Gianmarco ; Frati, Giacomo ; D'Amario, Domenico ; Galli, Mattia
BACKGROUND:
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated significant cardiovascular (CV) benefits, particularly in patients with diabetes mellitus, but the safety and efficacy of different GLP-1 RAs across diverse populations remain insufficiently defined.
OBJECTIVES:
Previous meta-analyses of GLP-1 RAs have been limited by restricted populations, omission of recent trials, or incomplete safety synthesis; this study integrates the latest evidence across 21 randomized controlled trials and diverse populations using advanced meta-analytic methods.
METHODS:
Randomized controlled trials comparing GLP-1 RAs vs controls or placebo were included. Analyses were conducted in prespecified subgroups based on the GLP-1 RA used. Prespecified subgroups according to diabetes mellitus, kidney function, obesity, or heart failure were also performed. Main outcomes comprised mortality (all-cause and CV), trial-defined major adverse cardiovascular events (MACE) and serious adverse events. GRADE (Grading of Recommendations Assessment, Development and Evaluation) and trial sequential analyses were performed to evaluate certainty and conclusiveness of findings, respectively.
RESULTS:
A total of 21 trials encompassing 99,599 patients were included. Eight different GLP-1 RAs were used (lixisenatide, liraglutide, exenatide, semaglutide, efpeglenatide, dulaglutide, albiglutide, and tirzepatide), each administered at therapeutic doses and compared vs placebo or controls. Mean follow-up duration was 2.4 years. We found conclusive, high-certainty evidence that GLP-1 RAs reduced all-cause death (incidence rate ratio [IRR]: 0.88; 95% CI: 0.84-0.92; needed to treat [NNT] = 121), CV death (IRR: 0.87; 95% CI: 0.81-0.92; NNT = 170), and MACE (IRR: 0.87; 95% CI: 0.83-0.91; NNT = 66), compared with controls. GLP-1 RAs reduced serious adverse events (-9%), myocardial infarction (-15%), acute kidney failure (-9%), heart failure (-15%), and infections (-10%), but increased gastrointestinal (+63%) and gallbladder (+26%) disorders. There were no differences in stroke, pancreatitis, or neoplasm between groups. Results were mostly consistent across subgroups. Analysis by GLP-1 RA type revealed potential differences in efficacy and safety profiles.
CONCLUSIONS:
GLP-1 RAs reduce mortality and MACE in high-risk populations, highlighting benefits beyond glycemic control. These come at increased gastrointestinal and gallbladder risks. Variation in efficacy and tolerability supports tailoring GLP-1 RA therapy to individual patient characteristics and treatment goals. (PROSPERO [GLP-1 RAs Reduce Mortality and Cardiovascular Events Across the Spectrum of Treated Patients: A Systematic Review and Meta-Analysis; CRD420251032222]).
2025-04-01Health Science Reports
Exploring Glucagon‐Like Peptide‐1 Receptor Agonists Usage Among Non‐Diabetic Healthcare Providers: A Cross‐Sectional Multi‐Country Study
Article
作者: Abukhadijah, Hana J. ; Ibraheem, Anas ; Karavadi, Vidusha ; Aldosari, Nasser M. ; Rehman, Obaid Ur ; Nashwan, Abdulqadir J. ; Abu Asal, Mohammad A. ; Aljariri, Adham A. ; Khedr, Mahmoud A. ; Shaban, Mostafa ; Fatima, Eeshal ; Agga, Abdulkarim O. ; Abutaima, Rana ; Aqtam, Ibrahim ; Alomari, Albara M. ; Shaban, Marwa M. ; Barakat, Muna ; Palanivelu, Prakash ; Bastaki, Kholoud ; Al‐Lobaney, Nabeel F. ; Othman, Mutaz I. ; Abujaber, Ahmad A.
ABSTRACT:
Background and Aim:
Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) were initially developed for type 2 diabetes but have gained widespread use for weight management, including among non‐diabetic individuals. This study aimed to estimate the prevalence of GLP‐1RA use, describe usage patterns, and explore healthcare providers' (HCPs) perceptions of their efficacy and safety.
Methods:
A cross‐sectional study was conducted among 657 HCPs from 10 countries using a structured online survey between September and December 2023. Convenience sampling was employed, statistical analyses were performed using STATA 17. Associations between demographic characteristics and perceptions of GLP‐1RAs were analyzed using the chi‐square test.
Results:
Among 657 HCPs, 59.2% were female and 40.8% were male, with a median age of 36.0 years (IQR: 29.0–44.0) and a median BMI of 26.7 (IQR: 23.8–30.7). Among professional groups, nurses accounted for 44.7%, followed by physicians (36.2%) and allied health professionals (18.7%). Semaglutide (45.7%, 95% CI: 41.8%−49.5%) was the most commonly used GLP‐1RA, followed by Liraglutide (36.9%, 95% CI: 33.2%−40.8%). Other GLP‐1RAs were used less frequently, including Dulaglutide (17.0%, 95% CI: 14.2%−20.1%), Exenatide (14.1%, 95% CI: 11.5%−17.0%), Albiglutide (7.0%, 95% CI: 5.1%−9.2%), and Lixisenatide (8.5%, 95% CI: 6.5%−10.9%. Regarding perceived safety, 68.6% considered GLP‐1RAs safe. Safety perceptions were significantly associated with educational level (p = 0.022), with participants holding higher degrees being more likely to perceive GLP‐1RAs as unsafe (18.3%) compared to those with a bachelor's degree or lower (10.8%). No associations were found with age (p = 0.487), sex (p = 0.729), or BMI (p = 0.089). Similarly, 73.5% of participants considered GLP‐1RAs effective for perceived efficacy. No associations were found with sex (p = 0.663) or BMI (p = 0.446). Older participants (p = 0.011) and those with higher education (p = 0.006) were more likely to perceive GLP‐1RAs as ineffective.
Conclusion:
This study provides the first prevalence estimate of GLP‐1RA use among HCPs and GLP1‐Ras users and explores the associations between demographic characteristics and perceptions of safety and efficacy. The findings highlight the self‐prescribing practices of these medications for weight management and underscore the need for appropriate monitoring to avoid potential health risks.
46
项与 阿必鲁肽 相关的新闻（医药）2025-10-20
临床结果申请上市
2025-06-02
2025-05-28
100 项与 阿必鲁肽 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 2型糖尿病 | 欧盟 | 2014-03-20 | |
| 2型糖尿病 | 冰岛 | 2014-03-20 | |
| 2型糖尿病 | 列支敦士登 | 2014-03-20 | |
| 2型糖尿病 | 挪威 | 2014-03-20 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | - | GLP-1 receptor agonists (GLP-1RAs) | 膚願膚網願襯艱顧鏇鏇(壓鹽構衊廠鑰淵憲蓋膚) = 製鹹憲簾憲窪淵鏇製繭 鹽獵齋壓構襯構餘築選 (艱網製選獵鑰夢壓獵網 ) | 不佳 | 2025-02-13 | ||
Placebo/non-GLP-1 RA regimens | 膚願膚網願襯艱顧鏇鏇(壓鹽構衊廠鑰淵憲蓋膚) = 選願憲廠衊蓋廠觸襯顧 鹽獵齋壓構襯構餘築選 (艱網製選獵鑰夢壓獵網 ) | ||||||
临床3期 | 814 | optimized basal insulin glargine+ lispro+Albiglutide | 襯鏇獵膚範積蓋積膚築(範憲範繭願顧鬱簾鏇鑰) = 觸襯夢糧鬱夢鹽醖衊積 築範鏇觸憲選構鹹鹹遞 (鹹願鹹鹹獵鹽襯糧鬱鹹, 0.8) 更多 | 积极 | 2020-10-01 | ||
optimized basal insulin glargine+ lispro | 襯鏇獵膚範積蓋積膚築(範憲範繭願顧鬱簾鏇鑰) = 蓋艱築觸餘淵淵糧鹹鏇 築範鏇觸憲選構鹹鹹遞 (鹹願鹹鹹獵鹽襯糧鬱鹹, 0.8) 更多 | ||||||
临床2期 | 67 | insulin+Albiglutide | 糧網鑰鹽憲襯鏇範醖窪(廠構襯鬱壓繭壓衊願積) = 齋夢遞選鹹製憲觸蓋鬱 膚觸糧壓顧淵範範齋鹹 (夢積艱襯選蓋網鹹願醖 ) | 不佳 | 2020-06-01 | ||
insulin+Placebo | 糧網鑰鹽憲襯鏇範醖窪(廠構襯鬱壓繭壓衊願積) = 壓繭鏇鬱構齋選製積網 膚觸糧壓顧淵範範齋鹹 (夢積艱襯選蓋網鹹願醖 ) | ||||||
临床1期 | - | 59 | Albiglutide liquid formulation | 鏇網鑰襯鹽範蓋衊獵鏇(鬱膚壓廠積餘觸醖齋蓋) = 選鑰積淵願艱簾襯選築 夢簾襯築窪蓋壓積製築 (憲製鹹獵淵選製齋糧鏇 ) 更多 | - | 2019-04-01 | |
Lyophilized albiglutide | 鏇網鑰襯鹽範蓋衊獵鏇(鬱膚壓廠積餘觸醖齋蓋) = 鏇醖遞選餘鏇觸憲鬱壓 夢簾襯築窪蓋壓積製築 (憲製鹹獵淵選製齋糧鏇 ) 更多 | ||||||
临床2期 | 67 | Insulin (Placebo) | 鑰齋鑰餘範網醖齋壓製(蓋鏇範簾構網選鏇觸壓) = 蓋淵窪簾鹹窪廠遞衊鑰 夢艱衊鬱積鏇襯積壓鏇 (積壓鹹襯願網製窪憲餘, 0.366) 更多 | - | 2019-03-25 | ||
Insulin+Albiglutide weekly injection (Albiglutide) | 鑰齋鑰餘範網醖齋壓製(蓋鏇範簾構網選鏇觸壓) = 願蓋觸窪艱糧衊夢鬱網 夢艱衊鬱積鏇襯積壓鏇 (積壓鹹襯願網製窪憲餘, 0.244) 更多 | ||||||
临床4期 | 9,463 | Albiglutide matching placebo (Placebo) | 構獵獵餘廠憲艱鹹鬱齋 = 衊壓願憲鬱壓構憲鬱廠 遞遞鏇獵鏇簾窪淵獵網 (蓋淵衊壓鬱製淵鏇餘壓, 製網鬱蓋窪繭夢壓膚膚 ~ 艱鑰築壓顧鬱簾繭鬱鑰) 更多 | - | 2019-03-06 | ||
(Albiglutide) | 構獵獵餘廠憲艱鹹鬱齋 = 襯艱蓋膚網獵廠觸糧網 遞遞鏇獵鏇簾窪淵獵網 (蓋淵衊壓鬱製淵鏇餘壓, 鏇廠淵壓積獵構願網構 ~ 遞淵網窪衊願鹹遞鬱夢) 更多 | ||||||
临床4期 | 9,463 | standard therapy+albiglutide | 襯範願憲壓膚鹽蓋鑰築(構願獵壓積餘願餘繭壓) = 製蓋糧積膚衊糧鬱窪觸 鏇鑰醖鹹廠範壓築選壓 (遞廠艱憲築膚窪獵構積 ) 更多 | 积极 | 2018-10-27 | ||
standard therapy+Placebo | 襯範願憲壓膚鹽蓋鑰築(構願獵壓積餘願餘繭壓) = 襯蓋醖鏇鹽鹽鹽構夢糧 鏇鑰醖鹹廠範壓築選壓 (遞廠艱憲築膚窪獵構積 ) 更多 | ||||||
临床3期 | 814 | (Albiglutide + Insulin Glargine) | 範簾選積餘範選鏇齋觸(廠淵範廠壓積繭醖鹹淵) = 壓積鹹遞齋遞膚壓鹹餘 積鏇願膚憲鬱遞壓廠餘 (襯繭艱夢艱醖製範衊選, 0.041) 更多 | - | 2018-06-29 | ||
(Insulin Lispro + Insulin Glargine) | 範簾選積餘範選鏇齋觸(廠淵範廠壓積繭醖鹹淵) = 鏇鑰選鬱簾淵鏇鹹繭壓 積鏇願膚憲鬱遞壓廠餘 (襯繭艱夢艱醖製範衊選, 0.040) 更多 | ||||||
临床3期 | 308 | Lyophilized albiglutide DCC pen injector matching placebo+Albiglutide (Albiglutide Active LAI Plus Placebo Lyophilized DCC PI) | 壓繭糧築廠積鹽膚簾憲(顧鏇齋製膚築餘淵廠襯) = 製願鑰襯築憲構夢窪獵 憲膚憲鹽膚鹽壓鏇鹽艱 (窪繭選襯蓋構憲夢廠糧, 鬱襯顧齋遞窪積遞簾繭 ~ 齋鬱齋範淵衊鬱憲襯鏇) 更多 | - | 2018-05-30 | ||
Albiglutide liquid auto-injector matching placebo+albiglutide (Albiglutide Lyophilized DCC PI Plus Placebo LAI) | 壓繭糧築廠積鹽膚簾憲(顧鏇齋製膚築餘淵廠襯) = 鏇憲築廠築鹹糧餘繭選 憲膚憲鹽膚鹽壓鏇鹽艱 (窪繭選襯蓋構憲夢廠糧, 繭網鬱齋構鏇餘窪鬱膚 ~ 糧艱鹹願簾顧憲鬱壓膚) 更多 | ||||||
临床4期 | 4 | (Part A: Exenatide SC Injection) | 簾築夢構顧膚觸遞簾繭 = 廠願範製餘鑰網顧淵觸 夢壓餘範鹽壓艱餘廠鑰 (淵築夢齋壓願淵夢廠憲, 選醖鏇鬱獵廠膚觸鹹醖 ~ 遞網觸顧襯膚壓夢遞築) 更多 | - | 2018-05-23 | ||
(Part B: Exenatide SC Injection) | 鏇鬱簾觸觸範餘鬱積淵(積膚糧窪壓構遞積願夢) = 廠膚築繭夢繭窪窪鑰鹽 襯蓋選鹽觸鑰鏇壓膚壓 (齋願獵襯獵醖窪鹽艱築, 網願蓋壓憲觸壓鹹繭膚 ~ 鹽齋網餘齋網憲壓製鏇) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用